guid re-affirmed give
thought hif dialysi
guidanc mostli in-lin tax share higher
report ep beat consensu driven sg invest
incom tax wors expect medic loss ratio mostli
contain commerci segment also gave detail guidanc roughli
in-lin expect although tax somewhat higher share somewhat
lower forecast core busi remain track
trim ep wors line item roll est
po base estimate vs previous reiter
buy rate expect strong momentum upsid
miss maintain trend issu
manag care compani miss quarter follow
compani maintain see trend
issu reiter commerci trend expect /- in-lin
instead attribut miss wors expect acuiti
commerci busi healthi group switch self-insur despit mco
deni trend issu proprieti survey countless industri data point
suggest otherwis overal risk rise trend appear higher commerci
govern program
fischbeck focu worri esrd
quarter focu upcom chang medicar advantag
elig dialysi industri talk potenti
headwind analysi full analysi walk background
methodolog key takeaway chang summari base case impli
expos could face ep headwind howev
bearish scenario could result hit given industry-wid issu
plan adjust benefit off-set increas cost potenti magnitud
shift larg degre shift unknown could take coupl
year normal expect health insur fee hif repeal would
off-set earn impact could limit upsid depend play
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
one largest manag care
organ unit state offer health
insur member govern
commerci segment compani focu
medicar advantag also particip
govern program includ tricar
medicaid compani also commerci
busi offer medic specialti product
strong player fastest grow
market coverag number catalyst
repo creat signific upsid potenti
estim risk upsid includ potenti
share repurchas sever non-healthcar
rate potenti hif repeal
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu upcom chang end stage renal
diseas esrd elig industri talk
potenti headwind analysi full analysi walk
background methodolog key takeaway upcom chang summari
base case impli expos could face ep headwind
howev bearish scenario could result hit given
industry-wid issu plan adjust benefit off-set increas cost
potenti magnitud shift larg degre shift unknown
could take coupl year normal expect hif repeal would
off-set earn impact could limit upsid depend play
note next data point come tonight advanc rate notic part
includ propos esrd capit rate risk adjust
control market get earn
thu expos centuri cure phase-in upcom
esrd chang base upon analysi state exposur likelihood
differ popul switch exposur averag higher
esrd preval state state medigap avail dialysi patient
highlight yesterday one major driver
base case assumpt shift like reduc hum earn
reason bear scenario would reduc ep
forecast might take year shift occur
incent dialysi provid shift patient impact could front-end
load everi shift would reduc ep assum rate
inadequaci delta addit rate delta would reduc ep
note talk potenti impact cure earn
potenti mispric
tabl expos potenti impact cure act
ep sensit analysi increas dialysi penetr potenti rate adequaci differenti
background centuri cure act
centuri cure act cure allow medicare-elig individu exist
end-stag renal diseas esrd enrol medicar advantag begin jan
current way esrd patient alreadi
enrol experienc kidney failur move dialysi today
patient alreadi diagnos esrd isnt abl sign
instead would sign tradit medicar medicar fee-for-servic
medicar ff patient shift potenti becom signific headwind
plan doesnt adequ reimburs plan high acuiti natur
mco commentari mix impact
quantifi impact cure compani talk
past coupl month cite headwind number
fact call like mean could percent impact
meanwhil say make money esrd patient
recent earn call investor present made point
discuss upcom impact cure mention current less
member esrd appear concern around esrd rate
low potenti patient today sicker
averag wont reflect rate addit compani often
cite network adequaci rule advoc loosen focu
network adequaci rule give provid bargain power lead
premium rate receiv could impli like toward higher
end industri averag rate pay provid
hum commentari differ
two largest player one would expect rel
similar commentari impact shift dialysi patient howev
like sever reason much cautiou
like lose money dialysi like make money
obviou reason go back analysi averag profit
appear much like make money first actual
target margin wherea like mean
els equal make larg enough margin non-dialysi cost
off-set premium pay dialysi cost addit hum
commentari need chang network adequaci rule impli us
like pay premium dialysi compani
push popul loss categori meanwhil one
aggress negoti provid rate particularli dialysi
compani actual su tactic shift patient onto exchang
combin averag margin like averag premium
provid mean may actual make money patient
tabl plan inher disadvantag pay treatment
sensit analysi impli econom esrd capit rate vs ff
base rate dialysi
annual ff esrd
non-esrd cost impli capit
pre-tax profit non-esrd built rate
premium ff
esrd cost plan
increment esrd cost plan rate
expos addit less profit dialysi
expos estim get
earn get result neg shift
impact hum ep
chart averag exposur earn
estim earn exposur product
might talk number front hif
health insur fee hif repeal size impact
hif like larger result temptat
add amount normal lt growth guidanc come
estim without know develop
rate updat like want keep expect low clariti
result like play potenti headwind
see tailwind hif
three key variabl impact analysi profit patient
rate appropri mani patient shift set rate
appropri alreadi analyz profit rate appropri
tabl analyz shift whether rate appropri
given current dialysi penetr rate vs broader rate
signific opportun larg swing enrol believ
main reason penetr current averag
patient kidney failur cant choos current way esrd
patient alreadi enrol experienc
kidney failur move dialysi today patient isnt abl sign
alreadi diagnos esrd instead would sign
medicar supplement great altern particularli akf
pay peopl dont realiz signific cost share
tradit medicar program hospit deduct copay see doctor
copays/deduct fill script coinsur outpati procedur etc
result signific pocket liabil peopl sick use
system less senior simpli medicar ff rest
popul sort supplement coverag plan
medigap retire health coverag dualli elig
medicar medicaid
icar beneficiari purchas supplement icar plan aka supp
medigap significantli reduc copay coinsur deduct
tradit medicar program without implement network
requir catch premium polici quit high
could sever hundr dollar per month limit much medicar
popul might choos option note american kidney fund akf
chariti gear toward help peopl esrd improv insur
coverag help peopl pay commerci premium help peopl
buy medigap coverag current akf pay medigap
premium peopl subsid way limit cost share
without network requir compel option
dual under-penetr gener speaking- although senior
medicar advantag almost dual medicar advantag
structur reason lower penetr import like
sinc beneficiari also qualifi medicaid medicaid pay
pocket cost might see need extra benefit plan
provid dialysi patient dual elig nation averag
els equal one would expect penetr dialysi lower
cure act address first reason state medigap avail
would expect see signific adopt state medigap option
would expect see shift less averag dual
popul would expect penetr move toward averag
mco higher exposur averag
patient state without medigap avail like
switch dual differ incent switch non-dual
compani sell plan impact risk see higher expect
membership shift estim specif enrol impact factor
geograph exposur state averag esrd preval well state
allow individu purchas supplement coverag sinc
highli incentiv switch due lack afford option
weigh factor found expos potenti wave
new dialysi patient vs market share could help explain
talk cure potenti headwind
tabl public mco overli expos new wave dialysi patient
market share vs estim share new dialysi patient
new dialysi patient
risk rate wont suffici
econom impact analysi outlin section assum esrd
capit rate suffici least accur reflect cost
treat patient ff program howev evid
suggest rate might suffici industri argu
exampl sinc esrd rate highli volatil vs broader non-esrd
rate neg time vs neg updat core rate
fact one year repres cumul rate updat sinc
without year rate would larg flat vs core exclud
updat volatil suggest difficulti accur captur true
cost treat dialysi patient patient popul would expect larg
chart esrd rate volatil impli cost patient hard predict
esrd vs non-esrd rate updat time
miscalcul cost compani mispric margin could
repeat analysi outlin tabl instead assum
adequ rate would need higher given rate increas
despit dialysi popul rel stabl popul year
year would impli actual cost serv new esrd patient shift
closer year new cost assumpt impli non-esrd cost
actual year sinc good visibl esrd ff cost
mean addit cost potenti captur
capit rate set addit unforeseen cost take impli margin
outlin tabl esrd patient
given say make money dialysi appear today
rate would far appropri howev likelihood incorrectli
predict cost particularli high go unknown
amount migrat membership ff whenev larg sudden
migrat membership becom difficult predict acuiti healthier
averag peopl switch sicker averag peopl switch therefor set
adequ rate fact mco lost hundr million dollar earli
year exchang one exampl dynam
final note could set rate appropri plan could mispric
plan risk everi year risk happen
new popul enter market higher averag risk higher
compani cite averag exposur state high dialysi
preval state dont medigap peopl
therefor whether rate incorrect risk pool shift sever
expect plan mis-pric potenti compani could see rate
wors expect
tabl underpay plan esrd patient estim potenti margin
sensit analysi variou insuffici rate scenario plan esrd patient
base rate dialysi
annual ff esrd
non-esrd cost impli capit
pre-tax profit non-esrd built rate
rate increas need adequ rate
non-esrd cost impli adequ rate
increment cost reflect rate
premium ff
esrd cost plan
increment esrd cost plan rate
cant plan price
given industry-wid issu plan adjust benefit off-set
increas cost howev state potenti magnitud shift larg
degre shift unknown make difficult industri
consist price vs someth straightforward like health insur fee result
risk year disrupt although time headwind
revers compani build higher cost bid
point still unclear extent upcom esrd chang
plan given mix commentari industri unknown premium
compani pay dialysi compani magnitude/tim shift given
vari incentives/lev across stakehold final rate get publish
mco set bid plan get clariti potenti
impact model headwind ep shift addit
assumpt keep benefit hif repeal overal
reason assumpt like prove conserv see
upsid
strong guidanc still leav room growth
shown there level histor conservat come hum
initi guidanc conservat give us confid despit previous talk
number abl deliv meaning ep growth despit
return hif year
guidanc reflect confid hum lt growth stori
expect adj ep rang
midpoint year year bridg ep note expect
gain per share retail busi group specialti
hc servic share repo re-invest per share back
busi lose corpor lose tax return
hif bridg expect adj ep midpoint overal
outlook consist expect compani note expect
realiz bit full year earn impli ep
consolid revenu expect increas
print guid come estim driven compani
expect group specialti segment est
although off-set lower outlook segment
estimate
forecast retail segment revenu y/i growth
mid expect strong perform continu
individu enrol grow live midpoint group grow
live midpoint call note abl invest
out-performance bid caus expect grow
individu book least market growth rate year medicar stand-alone
pdp expect see loss live improv last expect
despit compani still expect strong ebitda growth pharmaci
busi pre-tax incom retail busi expect
midpoint y/i growth also forecast retail segment
midpoint higher street estim
group specialti segment revenu expect impli
y/i growth guidanc midpoint come
consensu group commerci fully-insur membership expect decreas
live midpoint driven loss larg group account healthcar servic
segment adj ebitda outlook midpoint came estimate
impli y/i growth assum growth pharmaci busi continu
follow trend higher script volum ddition compani
expect strong home health growth expect segment contribut
adj ep
furthermor provid oper cost ratio guidanc mid
y/i exclud company-st hif impact guidanc would
y/i commerci cost trend expect
/- rel stabl seen past year
flow oper guidanc estim
capital-expenditure guidanc mid impli y/i growth driven
joint ventur partnership wca addit continu target debt-
to-capit ratio will increas strateg opportun
lastli tax rate guidanc expect
coupl hundr thousand
group specialti segment
chang year-end medic membership prior year end
group specialti segment
group specialti segment
weight averag share count dilut ep
flow oper
chang mid
po base ep estim premium histor
averag justifi strong growth trajectori expect core
upsid risk potenti share repurchas sever non-healthcar catalyst
includ tax reform higher interest rate potenti hif repeal downsid risk
regular industri sensit point cost trend rate well unknown
new administr chanc hif repeal fall
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
